Search Results - "Van Ojik, H H"

Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy by Bleeker, Wim K, Lammerts van Bueren, Jeroen J, van Ojik, Heidi H, Gerritsen, Arnout F, Pluyter, Marielle, Houtkamp, Mischa, Halk, Ed, Goldstein, Joel, Schuurman, Janine, van Dijk, Marc A, van de Winkel, Jan G. J, Parren, Paul W. H. I

“…Epidermal growth factor receptor (EGF-R) overexpression is common in a large number of solid tumors and represents a negative prognostic indicator…”
Get full text

No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial by van Gorkom, Gwendolyn N Y, Boerenkamp, Lara S, Gijsbers, Birgit L M G, van Ojik, Heidi H, Wodzig, Will K W H, Wieten, Lotte, Van Elssen, Catharina H M J, Bos, Gerard M J

“…Vitamin C is an important micronutrient for various immune cells. It increases phagocytic cell function and is necessary for T and natural killer (NK) cell…”
Get full text

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc RI × anti-HER-2 neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer by REPP, R, VAN OJIK, H. H, DEO, Y. M, BLIJHAM, G. H, KALDEN, J. R, DE WINKEL, J. G. J. Van, GRAMATZKI, M, VALERIUS, T, GROENEWEGEN, G, WIELAND, G, OETZEL, C, STOCKMEYER, B, BECKER, W, EISENHUT, M, STEININGER, H

“…A phase I study of the bispecific antibody MDX-H210 in combination with granulocyte colony-stimulating factor (G-CSF) was performed in stage IV breast…”
Get full text

Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma by van Spriel, Annemiek B., van Ojik, Heidi H., Bakker, Annie, Jansen, MarcoJ.H., van de Winkel, JanG.J.

“…Antibody-reliant destruction of tumor cells by immune effector cells is mediated by antibody-dependent cellular cytotoxicity, in which Fc receptor (FcR)…”
Get full text

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma by Kruit, Wim H.J., van Ojik, Heidi H., Brichard, Vincent G., Escudier, Bernard, Dorval, Thierry, Dréno, Brigitte, Patel, Poulam, van Baren, Nicolas, Avril, Marie‐Françoise, Piperno, Sophie, Khammari, Amir, Stas, Marguerite, Ritter, Gerd, Lethé, Bernard, Godelaine, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, Alexander M.M., Marchand, Marie

“…The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a…”
Get full text

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations by VAN OJIK, Heidi H, BEVAART, Lisette, DAHLE, Christopher E, BAKKER, Annie, JANSEN, Marco J. H, VAN VUGT, Martine J, VAN DE WINKEL, Jan G. J, WEINER, George J

“…Immunostimulatory CpG oligodeoxynucleotides (ODNs) can enhance the therapeutic effect of monoclonal antibodies (mAbs) by enhancing antibody-dependent…”
Get full text

IL-12: a promising adjuvant for cancer vaccination by PORTIELJE, Johanna E. A, GRATAMA, Jan Willem, VAN OJIK, Heidi H, STOTER, Gerrit, KRUIT, Wim H. J

“…The clinical development of interleukin 12 (IL-12) as a single agent for systemic cancer therapy has been hindered by its significant toxicity and…”
Get full text

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer by VAN OJIK, H. H, REPP, R, GROENEWEGEN, G, VALERIUS, T, VAN DE WINKEL, J. G. J

Get full text

Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy by van Ojik, H.H, Valerius, T

“…Bispecific antibodies constitute a novel approach to improve antibody efficacy. In vitro, constructs to recruit myeloid effector cells have been extensively…”
Get full text

Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients by Van Gool, A R, Van Ojik, H H, Kruit, W H J, Mulder, P G H, Fekkes, D, Bannink, M, Scharpé, S, Stoter, G, Eggermont, A M M, Maes, M, Verkerk, R

“…Immunotherapy with interferon-alpha (IFN-alpha) induces neuropsychiatric side effects, most notably depression. In hepatitis patients treated with IFN-alpha,…”
Get more information

FcγRI (CD64) Contributes Substantially to Severity of Arthritis, Hypersensitivity Responses, and Protection from Bacterial Infection by Ioan-Facsinay, A, de Kimpe, S.J, Hellwig, S.M.M, van Lent, P.L, Hofhuis, F.M.A, van Ojik, H.H, Sedlik, C, da Silveira, S.A, Gerber, J, de Jong, Y.F, Roozendaal, R, Aarden, L.A, van den Berg, W.B, Saito, T, Mosser, D, Amigorena, S, Izui, S, van Ommen, G-J.B, van Vugt, M, van de Winkel, J.G.J, Verbeek, J.S

“…The high-affinity receptor for IgG, FcγRI, shares its capacity to bind IgG2a immune complexes (IgG2a-IC) with the low-affinity receptor FcγRIII and complement…”
Get full text

CpG oligodeoxynucleotides enhance FcγRI-mediated cross presentation by dendritic cells by Bevaart, Lisette, Van Ojik, Heidi H., Sun, Amanda W., Sulahian, Timothy H., Leusen, Jeanette H. W., Weiner, George J., van de Winkel, Jan G. J., Van Vugt, Martine J.

“…Dendritic cells (DC) can trigger naive CD8+ T cell responses by their capacity to cross-present exogenous antigens via the major histocompatibility complex…”
Get full text

Immunotherapeutic perspective for bispecific antibodies by van Spriel, Annemiek B, van Ojik, Heidi H, van de Winkel, Jan G.J

“…Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human…”
Get full text

Pegylated interferon-α2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations by Van Gool, Arthur R, van Ojik, Heidi H, Kruit, Wim H. J, Bannink, Marjolein, Mulder, Paul G. H, Eggermont, Alexander M. M, Stoter, Gerrit, Fekkes, Durk

“…Our objective was to study the influence of pegylated interferon-α2b (PEG-IFN-α) on the metabolism of amino acids and pteridines. We used an exploratory study…”
Get full text

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: Efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fc gamma receptor I bispecific antibodies by Heijnen, IAFM, Rijks, LJM, Schiel, A, Stockmeyer, B, van Ojik, HH, Dechant, M, Valerius, T, Keler, T, Tutt, AL, Glennie, MJ, van Royen, EA, Capel, PJA, van de Winkel, JGJ

“…Abs are able to induce inflammatory antitumor responses by recruiting IgG Fc receptor (Fc gamma R)-bearing cytotoxic effector cells. We recently described the…”
Get full text

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies by Heijnen, IA, Rijks, LJ, Schiel, A, Stockmeyer, B, van Ojik, HH, Dechant, M, Valerius, T, Keler, T, Tutt, AL, Glennie, MJ, van Royen, EA, Capel, PJ, van de Winkel, JG

“…Abs are able to induce inflammatory antitumor responses by recruiting IgG Fc receptor (FcgammaR)-bearing cytotoxic effector cells. We recently described the…”
Get full text

Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy : The promise of monoclonal antibodies for the therapy of cancer by VAN OJIK, H. H, VALERIUS, T

Get full text

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection by Ioan-Facsinay, A, de Kimpe, S J, Hellwig, S M M, van Lent, P L, Hofhuis, F M A, van Ojik, H H, Sedlik, C, da Silveira, S A, Gerber, J, de Jong, Y F, Roozendaal, R, Aarden, L A, van den Berg, W B, Saito, T, Mosser, D, Amigorena, S, Izui, S, van Ommen, G J B, van Vugt, M, van de Winkel, J G J, Verbeek, J S

“…The high-affinity receptor for IgG, FcgammaRI, shares its capacity to bind IgG2a immune complexes (IgG2a-IC) with the low-affinity receptor FcgammaRIII and…”
Get full text

Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation by Van Ojik, Heidi, Biesma, Douwe H., Fijnheer, Rob, Hené, Ronald J., Lokhorst, Henk M., Jan, Sebo, Rooda, Eelkman, Verdonck, Leo F.

“…Thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation (BMT) is a serious complication that, in contrast to classic TTP, is generally not…”
Get full text

CpG oligodeoxynucleotides enhance Fc RI-mediated cross presentation by dendritic cells by Bevaart, L.

“…Dendritic cells (DC) can trigger naive CD8<+< T cell responses by their capacity to cross-present exogenous antigens via the major histocompatibility complex…”
Get full text